Andrea Schneider, M.S., Ph.D.


Pediatric Psychology


  • Assistant Research Scientist


Center for Mind and Brain

UC Davis MIND Institute

2825 50th St.
Sacramento, CA 95817
Driving Directions

Primary Phone:

Clinical Interests

From very early on in her academic career, Dr. Schneider focused on interdisciplinary research with brain-behavior interactions and acquired broad knowledge in clinical psychology and medical neuroscience, with specific training and expertise in ADHD, learning disabilities, and fragile X spectrum disorders.

Being also a clinical psychologist, her other area of interest is intervention research. She completed a pilot study of a phytopharmacological intervention (Ginkgo biloba) in dyslexia, and a study about the efficacy of neurofeedback in ADHD. Currently, Dr. Schneider's main research interest is the association between genetic and brain abnormalities underlying the neuropsychopathology, behavioral, and psychiatric symptoms in individuals with the fragile X mutations. Her focus on a number of psychophysiological indicators, like EEG/ERP measures in fragile X spectrum disorders and ASD, prepulse inhibition, eye tracking, and biofeedback.

Dr. Schneider is strongly committed to understanding, prevention, care, and cure of neurodevelopmental disorders.

Center/Program Affiliation

UC Davis MIND Institute
UC Davis Children's Hospital


M.S., University of Postdam, Potsdam, 2001

Ph.D., University of Postdam, Potsdam, 2007

B.S., University of Potsdam, Postdam, 1997

Internship: Psychological-Psychotherapeutic Ward (outpatient), Potsdam, 2002-04


UC Davis MIND Institute, Postdoctoral Fellow, Sacramento, CA, 2008-11

Professional Memberships

American Psychological Association (APA)

FENS (Federation of European Neuroscience Society), and the Center for Cognitive Studies, University Potsdam, Germany.

ffiliate of the ARTP (Autism Research and Treatment) program

MIND Institute

Select Recent Publications

Chonchaiya, W, Au, J, Schneider, A, Hessl, D, Harris, SW, Laird, M, Mu, Y, Tassone, F, Nguyen, DV, Hagerman, RJ. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Human Genetics, 2012; 131(4): 581-9.

Knox, A, Schneider, A, Abucayan, F, Hervey, C, Tran, C, Hessl, D, Berry-Kravis, E. Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS). Journal of neurodevelopmental disorders, 2012; 4(1): 2.

Sorensen, PL, Basuta, K, Mendoza-Morales, G, Gane, LW, Schneider, A, Hagerman, R, Tassone, F. A fragile X sibship from a consanguineous family with a compound heterozygous female and partially methylated full mutation male. American journal of medical genetics. Part A, 2012; 158A(5): 1221-4.

Wang, J.Y., Hessl, D., Iwahashi, C., Cheung, K., Schneider, A., Hagerman, R., Hagerman, P., Rivera, S. Influence of the fragile X mental retardation (FMR1) gene on the brain and working memory in men with normal FMR1 alleles. NeuroImage, 2012; 12(65C): 288-298.

Wang, JM, Koldewyn, K, Hashimoto, R, Schneider, A, Le, L, Tassone, F, Cheung, K, Hagerman, P, Hessl, D, Rivera, SM. Male carriers of the FMR1 premutation show altered hippocampal-prefrontal function during memory encoding. Frontiers in human neuroscience, 2012; 6: 297.

Winarni, TI, Schneider, A, Borodyanskara, M, Hagerman, RJ. Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome. Case Reports in Genetics, 2012: 280813.

Yang, JC, Chan, SH, Khan, S, Schneider, A, Nanakul, R, Teichholtz, S, Niu, YQ, Seritan, A, Tassone, F, Grigsby, J, Hagerman, PJ, Hagerman, RJ, Olichney, JM. Neural Substrates of Executive Dysfunction in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): a Brain Potential Study. Cerebral cortex, 2012; 1-10.

Hessl, D, Wang, JM, Schneider, A, Koldewyn, K, Le, L, Iwahashi, C, Cheung, K, Tassone, F, Hagerman, PJ, Rivera, SM. Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation. Biological psychiatry, 2011; 70(9): 859-65.

Bourgeois J.A., Seritan A.L., Casillas E.M., Hessl D., Schneider A., Yang Y., Kaur I., Cogswell J.B., Nguyen D.V., Hagerman R.J. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry. 2011; 72(2): 175-82.

Schneider, A., Ballinger, E., Chavez, A., Tassone, F., Hagerman, RJ., Hessl, D. Prepulse Inhibition in patients with fragile X-associated tremor ataxia syndrome. Neurobiol Aging, 2010; 33(6): 1045-1053.